Gujarat Themis Biosyn Limited Q4 FY25 results deck summary

Results deck of 20 May 2025, summarised by AI from the filing.

FY25 revenue ₹150.80 cr, EBITDA ₹68.84 cr, PAT ₹48.77 cr; new API unit operational from May 2025

Key takeaways

1. Guidance No forward guidance was provided in the presentation
2. Change Q4 FY24-25 revenue declined 10.18% YoY to ₹37.74 cr from ₹42.01 cr
3. Driver New API unit operational, production began May 2025, targeting US and Europe exports
4. Risk Volatility in inventory hampered overall sales and had a cascading effect on EBITDA levels

Original filing on BSE

Gujarat Themis Biosyn Limited Q1 FY27 results

As filed: Revenue ₹43.8 cr (+22% year on year), EBITDA ₹20.8 cr (+49% year on year), PAT ₹11.1 cr (+23% year on year), EBITDA margin 47.5% (+861 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹44.2 cr (+16% year on year), EBITDA ₹19.4 cr (+21% year on year), PAT ₹10.9 cr (−9% year on year), EBITDA margin 43.8% (+169 bps). Score 55 of 100, In line with trend. EBITDA margin rose 169 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: +8.8% in 30 days (Nifty 500: +2.1%).
• Q3 FY26: Revenue ₹43.4 cr, EBITDA ₹21.3 cr, PAT ₹12.5 cr, EBITDA margin 49.1%. Not scored. No result for the same quarter last year. Share price after the results: −9.3% in 29 days (Nifty 500: −4.0%).
• Q2 FY26: Revenue ₹42.0 cr, EBITDA ₹21.0 cr, PAT ₹14.0 cr, EBITDA margin 50.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.8% in 30 days (Nifty 500: −0.5%).
• Q1 FY26: Revenue ₹36.0 cr, EBITDA ₹14.0 cr, PAT ₹9.0 cr, EBITDA margin 38.9%. Not scored. No result for the same quarter last year. Share price after the results: −3.2% in 28 days (Nifty 500: −2.0%).
• Q4 FY25: Revenue ₹38.0 cr, EBITDA ₹16.0 cr, PAT ₹12.0 cr, EBITDA margin 42.1%. Not scored. No result for the same quarter last year. Share price after the results: −3.3% in 30 days (Nifty 500: +0.8%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gujarat Themis Biosyn Limited earnings call, investor presentation and press release summaries

• Q1 FY27: Earnings call (10 Aug 2026), Results deck (7 Aug 2026)
• Q4 FY26: Results deck (25 May 2026)
• Q3 FY26: Results deck (5 Feb 2026)
• Q2 FY26: Results deck (10 Nov 2025)
• Q1 FY26: Results deck (1 Aug 2025)
• Q4 FY25: Results deck (20 May 2025)
• Other events: Strategy deck (29 Jun 2026), Strategy deck (22 May 2026), Strategy deck (23 Apr 2026)